Scientists at Sanofi created digital counterparts of people with Pompe disease to support drug development and advance Pompe disease treatment. In a simulated clinical trial of digital twins with infantile-onset Pompe disease (IOPD), Sanofi’s Nexviazyme (avalglucosidase alfa), an enzyme replacement therapy, outperformed its first-generation Lumizyme (alglucosidase alfa)…
AI
Recent Posts
- I wonder about the questions my daughter hasn’t asked me yet
- TRPML1 activation may boost Pompe ERT effects in new cell study
- How a mother helps her daughter face Pompe disease treatment
- Muscle MRI may detect early changes in late-onset Pompe disease
- It’s hard on my child when home infusions interrupt summer fun